1. Home
  2. KD vs LEGN Comparison

KD vs LEGN Comparison

Compare KD & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kyndryl Holdings Inc.

KD

Kyndryl Holdings Inc.

HOLD

Current Price

$24.29

Market Cap

6.2B

Sector

Technology

ML Signal

HOLD

Logo Legend Biotech Corporation

LEGN

Legend Biotech Corporation

HOLD

Current Price

$19.07

Market Cap

5.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KD
LEGN
Founded
2020
2014
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.2B
5.9B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
KD
LEGN
Price
$24.29
$19.07
Analyst Decision
Buy
Buy
Analyst Count
5
14
Target Price
$39.60
$64.23
AVG Volume (30 Days)
1.8M
2.8M
Earning Date
02-04-2026
03-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.68
N/A
Revenue
$15,008,000,000.00
$909,045,000.00
Revenue This Year
$6.40
$68.20
Revenue Next Year
$3.60
$47.77
P/E Ratio
$14.42
N/A
Revenue Growth
N/A
74.75
52 Week Low
$23.28
$18.99
52 Week High
$44.20
$45.30

Technical Indicators

Market Signals
Indicator
KD
LEGN
Relative Strength Index (RSI) 33.76 33.26
Support Level $24.24 $20.21
Resistance Level $25.27 $23.88
Average True Range (ATR) 0.84 1.37
MACD -0.31 -0.14
Stochastic Oscillator 1.70 0.97

Price Performance

Historical Comparison
KD
LEGN

About KD Kyndryl Holdings Inc.

Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in Australia / New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Share on Social Networks: